Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression

References

• Gaulard PSS, Harris NL, Jaffe ES, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, et al. editors. WHO classification of tumours of haematopoietic and lymphoid tissues. IARC: Lyon, 2008. p. 350–351.
   Google Scholar
• Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med. 1993;328:1317–1321.
   PubMed Web of Science ®Google Scholar
• Kamel OW, van de Rijn M, Hanasono MM, et al. Immunosuppression-associated lymphoproliferative disorders in rheumatic patients. Leuk Lymphoma. 1995;16:363–368.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Watanabe R, Nemoto T, et al. Clinicopathological analyses in patients with other iatrogenic immunodeficiency-associated lymphoproliferative diseases and rheumatoid arthritis. Leuk Lymphoma. 2012;53:616–623.
   PubMed Web of Science ®Google Scholar
• Hoshida Y, Tomita Y, Zhiming D, et al. Lymphoproliferative disorders in autoimmune diseases in Japan: analysis of clinicopathological features and Epstein-Barr virus infection. Int J Cancer. 2004;108:443–449.
   PubMed Web of Science ®Google Scholar
• Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. Am J Hematol. 2007;82:1106–1109.
   PubMed Web of Science ®Google Scholar
• Hasserjian RP, Chen S, Perkins SL, et al. Immunomodulator agent-related lymphoproliferative disorders. Mod Pathol. 2009;22:1532–1540.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Okamoto M, Nakamine H, et al. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. Cancer Sci. 2010;101:1309–1313.
   PubMed Web of Science ®Google Scholar
• Ichikawa A, Arakawa F, Kiyasu J, et al. Methotrexate/iatrogenic lymphoproliferative disorders in rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are important predictors of disease progression and regression. Eur J Haematol. 2013;91:20–28.
   PubMed Web of Science ®Google Scholar
• Yamakawa N, Fujimoto M, Kawabata D, et al. A clinical, pathological and genetic characterization of methotrexate-associated lymphoproliferative disorders. J Rheumatol. 2014;41:293–299.
   PubMed Web of Science ®Google Scholar
• Inui Y, Matsuoka H, Yakushijin K, et al. Methotrexate-associated lymphoproliferative disorders: management by watchful waiting and observation of early lymphocyte recovery after methotrexate withdrawal. Leuk Lymphoma. 2015;56:3045–3051.
   PubMed Web of Science ®Google Scholar
• Maegawa S, Kuroda J, Kobayashi T, et al. Clinical manifestation and prognostic factors of 32 Japanese patients with autoimmune disease-associated diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56:785–788.
   PubMed Web of Science ®Google Scholar
• Simon TA, Thompson A, Gandhi KK, et al. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.
   PubMed Web of Science ®Google Scholar
• Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood. 2002;99:3909–3915.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• http://hla.or.jp
   Google Scholar
• Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458.
   PubMed Web of Science ®Google Scholar
• Tokuhira M, Kimura Y, Nemoto T, et al. Therapy-related myeloid neoplasm in methotrexate-associated lymphoproliferative disease in a rheumatoid arthritis patient. J Clin Exp Hematopathol. 2014;54:137–141.
   PubMedGoogle Scholar
• Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54:692–701.
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Takahashi Y, Yamashita H, et al. Clinical characteristics and incidence of methotrexate-related lymphoproliferative disorders of patients with rheumatoid arthritis. Mod Rheumatol. 2014;24:763–765.
   PubMed Web of Science ®Google Scholar
• Saito S, Kaneko Y, Yamaoka K, et al. Distinct patterns of lymphocyte count transition in lymphoproliferative disorder in patients with rheumatoid arthritis treated with methotrexate. Rheumatology (Oxford). 2017;56:940–946.
   PubMed Web of Science ®Google Scholar
• Saito S, Suzuki K, Yamaoka K, et al. Restoration of decreased lymphocyte counts and the shift to Th1 and effector memory CD8+ T cell subsets associate with spontaneous regression of lymphoproliferative disorders developed in RA patients treated with methotrexate. 2016 American College of Rheumatology Annual Meeting, #2569.
   Google Scholar
• Kameda T, Dobashi H, Miyatake N, et al. Association of higher methotrexate dose with lymphoproliferative disease onset in rheumatoid arthritis patients. Arthritis Care Res (Hoboken). 2014;66:1302–1309.
   PubMed Web of Science ®Google Scholar
• Tosato G, Steinberg AD, Blaese RM. Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med. 1981;305:1238–1243.
   PubMed Web of Science ®Google Scholar
• Balandraud N, Meynard JB, Auger I, et al. Epstein–Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. Arthritis Rheum. 2003;48:1223–1228.
   PubMed Web of Science ®Google Scholar
• Satou A, Kohno A, Fukuyama R, et al. Epstein–Barr virus-positive mucocutaneous ulcer arising in a post-hematopoietic cell transplant patient followed by polymorphic posttransplant lymphoproliferative disorder and cytomegalovirus colitis. Hum Pathol. 2017;59:147–151.
   PubMed Web of Science ®Google Scholar
• Ishida M, Hodohara K, Yoshii M, et al. Methotrexate-related Epstein-Barr virus-associated lymphoproliferative disorder occurring in the gingiva of a patient with rheumatoid arthritis. Int J Clin Exp Pathol. 2013;6:2237–2241.
   PubMed Web of Science ®Google Scholar
• Horie N, Kawano R, Kaneko T, et al. Methotrexate-related lymphoproliferative disorder arising in the gingiva of a patient with rheumatoid arthritis. Aust Dent J. 2015;60:408–411.
   PubMed Web of Science ®Google Scholar
• Hashimoto A, Chiba N, Tsuno H, et al. Incidence of malignancy and the risk of lymphoma in Japanese patients with rheumatoid arthritis compared to the general population. J Rheumatol. 2015;42:564–571.
   PubMed Web of Science ®Google Scholar
• Furukawa H, Oka S, Shimada K, et al. Human leukocyte antigen polymorphisms and personalized medicine for rheumatoid arthritis. J Hum Genet. 2015;60:691–696.
   PubMed Web of Science ®Google Scholar
• Oka S, Furukawa H, Kawasaki A, et al. Protective effect of the HLA-DRB1*13:02 allele in Japanese rheumatoid arthritis patients. PLoS One. 2014;9:e99453.
   PubMed Web of Science ®Google Scholar